a Students' Research Committee, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences , Tabriz , Iran.
b Road Traffic Injury Research Center, Tabriz University of Medical Sciences , Tabriz , Iran.
J Am Coll Nutr. 2018 Mar-Apr;37(3):223-233. doi: 10.1080/07315724.2017.1392264. Epub 2018 Jan 9.
There is a promising perspective regarding the potential effect of resveratrol in preventing and treating metabolic disturbances similar to that of calorie restriction. The aim of this study was to evaluate the effects of calorie-restricted (CR) diet on metabolic parameters and then to investigate whether resveratrol supplementation has beneficial effects similar to CR diet in patients with nonalcoholic fatty liver disease (NAFLD).
This randomized controlled clinical trial was conducted in 90 patients with NAFLD (males and females) aged 20 to 60 years with body mass index (BMI) ranging from 25 to 35 kg/m. Participants were assigned to one of three intervention groups as follows: The CR diet group (n = 30) received a prescribed low-calorie diet, the resveratrol group (n = 30) received 600 mg pure trans-resveratrol (2 × 300 mg) daily, and the placebo group (n = 30) received placebo capsules (2 × 300 mg) daily for 12 weeks. Fasting blood samples, anthropometric measurements, and dietary intake and physical activity data were collected for all participants at baseline and at the end of the trial.
CR diet significantly reduced weight (by 4.5%); BMI; waist circumference; waist-to-hip ratio; and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles in participants compared to resveratrol and placebo (all p < 0.05). Significant reductions in weight (by 1.1%) and BMI were found in the resveratrol group compared to the placebo group (p < 0.05). ALT, AST, and lipid profiles did not change significantly in the resveratrol group (all p > 0.05). No significant changes were seen in hepatic steatosis grade, serum glycemic parameters, and high-density lipoprotein cholesterol and sirtuin-1 levels in any group (all p > 0.05).
CR diet with moderate weight loss has favorable effects on NAFLD, and resveratrol supplementation induced weight loss but failed to mimic other aspects of CR diet. Future studies are warranted to evaluate the long-term and dose-dependent effects of resveratrol on metabolic diseases.
白藜芦醇在预防和治疗类似于热量限制的代谢紊乱方面具有潜在的效果,这一观点前景广阔。本研究旨在评估热量限制(CR)饮食对代谢参数的影响,然后研究白藜芦醇补充是否对非酒精性脂肪性肝病(NAFLD)患者具有类似于 CR 饮食的有益效果。
这项随机对照临床试验纳入了 90 名年龄在 20 至 60 岁之间、BMI 为 25 至 35kg/m 的男性和女性 NAFLD 患者,将其分为 3 组接受干预:CR 饮食组(n = 30)接受规定的低热量饮食,白藜芦醇组(n = 30)每日服用 600mg 纯反式白藜芦醇(2×300mg),安慰剂组(n = 30)每日服用 2×300mg 安慰剂胶囊,共 12 周。所有参与者在基线和试验结束时采集空腹血样、人体测量学指标、饮食摄入和体力活动数据。
与白藜芦醇和安慰剂组相比,CR 饮食显著降低了参与者的体重(降低 4.5%)、BMI、腰围、腰臀比和血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和血脂谱(均 p < 0.05)。与安慰剂组相比,白藜芦醇组的体重(降低 1.1%)和 BMI 显著降低(p < 0.05)。白藜芦醇组的 ALT、AST 和血脂谱没有明显变化(均 p > 0.05)。各组肝脂肪变性程度、血清血糖参数以及高密度脂蛋白胆固醇和 Sirtuin-1 水平均无明显变化(均 p > 0.05)。
适度减重的 CR 饮食对 NAFLD 有良好的效果,而白藜芦醇补充虽然诱导了体重减轻,但未能模仿 CR 饮食的其他方面。需要进一步的研究来评估白藜芦醇对代谢性疾病的长期和剂量依赖性影响。